GSK Investigational Site

Szigetvár 7900

0 studies enrolling now · 5 studies all time

What they study most

Anaemia, Aspergillosis, Allergic Bronchopulmonary, Asthma, Diabetes Mellitus, Type 2

Studies at this site

• An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) — Completed
• A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) — Completed
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) — Completed
• Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM) — Completed